The Scope of Pharma Business in India

Shiba Kalyan Giri*

1PG Diploma in Management, ITM Business School, Warangal, Telangana, India

ABSTRACT

The pharmaceutical industry is one of the demanding and dynamic sectors of Indian economy. As health care continues to grow and account for a significant portion of the economy the importance of the sector is increasing day by day. Successful pharmaceutical executives possess a broad business base, combined with an in-depth knowledge of the industry. Successful managers need to achieve a level of competence in the areas of fundamental management within the industry. The multinational companies had dominated the Indian market due to the lack of patient protection by the Indian Players. As the multinationals streamed out, the Indian players are facing the challenges and became niche in both the Indian as well world market. There are few companies those who are taking baby steps for the innovation of new drugs and doing R&D for the various diseases. The article is belongs to the present and future situation of Indian Pharma Markets and scope for the Indian and foreign player and regarding the opportunities.

INTRODUCTION

The number of sole Indian Pharma companies is fairly low in Indian Market. It is dominated by the foreign companies having the subsidiaries in India due to the cheap labor cost and talented scientist [1-2]. In the year 2002, over 20,000 pharmaceutical manufactures registered in India sold $9 billion worth of formulations and bulk drugs [3-5]. 85% of these formulations were sold in India while over 60% of the bulk drugs were exported, mostly to the United States and Russia [6]. Most of the players in the market are SMEs and at the same time it is controlled by the more than 250 companies which control of 70% of the total Indian market [7-10]. Most Pharma companies operating in India, even the multinationals, employ Indians almost exclusively from the lowest ranks to high level management. Homegrown pharmaceuticals, like many other businesses in India, are often a mix of public and private enterprise. In terms of global market India is growing at a10 % (approx) by every year [11-13].

INDIAN PHARMA SECTOR

The Indian pharmaceutical market is one of the demanding market for players and investors in the globe which possess the 3rd place in terms of volume and 13th place in terms of the value. The branded companies are dominating the market by 70 to 80 percent of the total market [14-17]. Indian is the largest provider of the generic drugs globally which is accounting for the 20 percent of the total global export in terms of volume [18-21]. The consolidation has become one of the important characteristic of the Indian Pharmaceutical market as the industry is highly fragmented. The country is having the large pool of talented man power in terms of scientist and engineers, who have the potentials to steer the industry ahead an even higher level. Let’s take an overview on the Indian Pharmaceutical Sector [21-24]. Today 80 percent of the antiviral drugs used globally to combat for HIV are supplied by the Indian player [25-29]. India produce the 40-70% of the WHO demanded for DPT and BCG and 90 percent of the measles vaccine. Seventy percent of the patients in the developing countries used to receive the Indian medicine through various international NGOs [30].
There are more than 10500 manufacturing units and over than 3000 companies are recorded in India out of which more than 1400 are WHO GMP approved manufacturing units. India has been accredited with approximately 1,105 CEPs, more than 950 TGA approvals and 584 sites approved by the USDA. Globally more than 90 per cent of formulations approvals for Anti-retroviral (ARVs), Anti-tubercular & Anti-malarial (WHO pre-qualified) has been granted to India. Manufacturing costs in India are approximately 35-40 per cent of those in the US due to low installation and manufacturing costs. India ranks amongst the top global generic formulation exporters in volume terms. There are 74 US FDA approved manufacturing in India which is more than any other country in the world. Almost 20 percent of new drug applications to the FDA are generally filled by the Indian countries.

**Export**

The export of drugs is calculated about $16.8 bn and the countries pharmaceutical industry accounts for about 1.4 per cent of the global pharmaceutical industry in value terms and 10 per cent in volume terms.

<table>
<thead>
<tr>
<th>Rank</th>
<th>Country</th>
<th>Value (US$)</th>
<th>Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>United States</td>
<td>$3.8 billion</td>
<td>32.9%</td>
</tr>
<tr>
<td>2</td>
<td>South Africa</td>
<td>$461.1 million</td>
<td>3.9%</td>
</tr>
<tr>
<td>3</td>
<td>Russia</td>
<td>$447.9 million</td>
<td>3.8%</td>
</tr>
<tr>
<td>4</td>
<td>United Kingdom</td>
<td>$444.9 million</td>
<td>3.8%</td>
</tr>
<tr>
<td>5</td>
<td>Nigeria</td>
<td>$385.4 million</td>
<td>3.3%</td>
</tr>
<tr>
<td>6</td>
<td>Kenya</td>
<td>$233.9 million</td>
<td>2%</td>
</tr>
<tr>
<td>7</td>
<td>Tanzania</td>
<td>$225.2 million</td>
<td>1.9%</td>
</tr>
<tr>
<td>8</td>
<td>Brazil</td>
<td>$212.7 million</td>
<td>1.8%</td>
</tr>
<tr>
<td>9</td>
<td>Australia</td>
<td>$182.1 million</td>
<td>1.6%</td>
</tr>
<tr>
<td>10</td>
<td>Germany</td>
<td>$178.8 million</td>
<td>1.5%</td>
</tr>
</tbody>
</table>

Data as per 2014 import.

**Product Development**

Indian Companies are starting on the research and development for the new opportunities with new environment. Although the initial stage investment is more and companies are lured by the promise of the hefty profit margin. Local firms are slowly investing more money in the R&D programs or forming the alliance to grab these opportunities. The Indian companies are merging with so many foreign players to avail this opportunities and creating the brand image in the global market.

**Little and medium ventures**

As promising as what's to come is for an entire, the standpoint for little and medium endeavors (SME) is not as brilliant. The extract structure changed since so that organizations now need to pay a 16% duty on the greatest retail value (MRP) of their items, rather than on the ex-industrial facility cost. Thus, bigger organizations cut back on outsourcing and what business is left moved to organizations with offices in the four tax-exempt states – Himachal Pradesh, Jammu and Kashmir, Uttaranchal, and Jharkhand. Therefore, countless producers moved their plant to these states, as it turned out to be verging on difficult to keep working in non-tax exempt zones. In any
case, in a matter of a few years the extract obligation was updated on two occasions, first it was diminished to 8% and afterward to 4%. Subsequently, the advantages of moving to a tax exempt zone were discredited. This brought about; plants in the tax exempt zones, to fire up outsider assembling [66-70]. Under this these manufacturing plants delivered merchandise under the brand names of different gatherings on employment work premise.

As SMEs grappled with the duty structure, they were likewise scrambling to meet the 1 July deadline for consistence with the reconsidered Schedule M Good Manufacturing Practices (GMP). While this ought to be valuable to customers and the business everywhere, SMEs have been thinking that it's hard to discover the assets to redesign their assembling plants, bringing about the conclusion of numerous offices [71-73]. Others contributed the cash to convey their offices to consistence, yet these operations were situated in non-tax-exempt states, making it hard to contend in the wake of the new extract charge [74-77].

Dissimilar to in different nations, the contrast amongst biotechnology and pharmaceuticals remains genuinely characterized in India, with biotech a much littler part of the economy. India represented 2% of the $41 billion worldwide biotech market and in 2003 was positioned third in the Asia-Pacific area and thirteenth on the planet in number of biotech. In 2004-5, the Indian biotech industry saw its incomes grow 37% to $1.1 billion [78-82]. The Indian biotech business sector is ruled by bio pharmaceuticals; 76% of 2004–5 incomes originated from bio pharmaceuticals, which saw 30% development a year ago. Of the incomes from bio-pharmaceuticals, immunizations drove the way, involving 47% of offers [83-88]. Biologics and expansive particle drugs tend to be more costly than little atom medications, and India wants to clear the business sector in bio-generics and contract fabricating as medications go off patent and Indian organizations update their assembling capacities.

Most organizations in the biotech division are to a great degree little, with just two firms softening 100 million dollars up incomes. Last time anyone checked there were 265 firms enlisted in India, more than 92% of which were fused in the most recent five years. The freshness of the organizations clarifies the business' high solidification in both physical and money related terms. Very nearly 30% of all biotech are in or around Bangalore, and the main ten organizations catch 47% of the business sector. The main five organizations were homegrown; Indian firms represent 72% of the bio-pharma area and 52% of the business as a whole. The Association of Biotechnology-Led Enterprises (ABLE) is planning to develop the business to $5 billion in incomes created by 1 million workers by 2009, and information from the Confederation of Indian Industry (CII) appear to propose that it is conceivable[89,90].

This segment depends to a great extent or totally upon a solitary source. Significant examination might be found on the discussion page. It would be ideal if you enhance this article by acquainting references with extra sources. (June 2016). The Indian biotech segment parallels that of the US from multiple points of view. Both are loaded with little new businesses while most of the business sector is controlled by a couple of effective organizations. Both are reliant upon government concedes and financial speculators for subsidizing in light of the fact that neither one of the wills be economically practical for a considerable length of time. Pharmaceutical organizations in both nations see development potential in biotechnology and have either put resources into existing new companies or wandered into the field themselves [91-93].

**Government Support**

The Indian government set up the Department of Biotechnology in 1986 under the Ministry of Science and Technology. From that point forward, there have been various administrations offered by both the focal government and different states to support the development of the business. India's science clergyman dispatched a system that gives charge motivating forces and gives to biotech new businesses and firms trying to grow and sets up the Biotechnology Parks Society of India to bolster ten biotech parks by 2010. Already restricted to rodents, creature testing was extended to incorporate substantial creatures as a feature of the priest's drive. States have begun to compete with each other for biotech business, and they are putting forth such treats as exclusion from VAT and different charges, money related help with licenses and appropriations on everything going from venture to land to utilities [94-96].

The biotechnology part confronts some significant difficulties in its journey for development. Boss among them is an absence of financing, especially for firms that are simply beginning. The undoubtedly wellsprings of assets are government allows and investment, which is a moderately youthful industry in India. Government awards are hard to secure, and due to the costly and indeterminate nature of biotech examination, financial speculators are hesitant to put resources into firms that have not yet built up an industrially reasonable item [97,98].

The legislature has tended to the issue of taught yet unfit hopefuls in its Draft National Biotech Development Strategy. This arrangement incorporated a proposition to make a National Task Force that will work with the biotech business to update the educational modules for undergrad and graduate study in life sciences and biotechnology. The administration's system additionally expressed goals to expand the quantity of PhD Fellowships recompensed
by the Department of Biotechnology to 200 every year. These HR will be further utilized with a "Bio-Edu-Grid" that will weave together the assets of the scholarly and exploratory modern groups, much as they are in the US \cite{99,100).

**CONCLUSION**

The pharmaceutical industry is one of the demanding and dynamic sectors of Indian economy. The opportunities for the Indian Pharma Industry in India are high with the support of the government and the multinational player playing in the globe. As per the data Indian Pharma companies are the valuable contributor to the foreign market. As we have the full of natural resources, funding support, liberal policy and talented manpower available, the scope for the sector is high.

**REFERENCES**